24 results about "Blood plasma" patented technology

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence id introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby mailing available a superior replacement of plasma-derived therapeutic immunoglobulin products.

An apparatus and method for performing surgery using plasma is described. In one exemplary embodiment, the apparatus includes a radiofrequency signal generator, a conditioning network coupled to the radiofrequency signal generator, and a catheter coupled to the conditioning network, the catheter including at least one electrode, such that the conditioning network conditions radiofrequency energy produced by the radiofrequency signal generator to create plasma at the at least one electrode of the catheter.

It is an object of the present invention to provide a solution for creating an effective method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis) without directly affecting the genetic apparatus of the ageing cells.

According to the invention this task is solved by administration into the blood circulation of the agent which inactivates extracellular blood plasma DNA; the extracellular blood DNA inactivating agent can be embodied in the form of an extracellular blood plasma DNA destroying agent; said extracellular blood plasma DNA destroying agent can be embodied in the form of an DNase enzyme; the extracellular blood plasma DNA inactivating agent can also be embodied in the form of an extracellular blood plasma DNA binding agent; the extracellular blood plasma DNA binding agent can be embodied in the form of anti-DNA antibodies; the extracellular blood plasma DNA inactivating agent can be administered in the form of an enzyme modifying the chemical composition of extracellular blood plasma DNA; the extracellular blood plasma DNA inactivating agent can be embodied in the form of an agent that stimulates synthesis or activity of endogenous deoxyribonuclease, or an agent that stimulates the synthesis of antibodies which capable to bind extracellular blood plasma DNA.

The invention belongs to the field of molecular biology and discloses a serum/plasma miRNA composition and use thereof. The miRNA composition comprises one or more of the following miRNAs: hsa-miR-122, hsa-miR-92a, hsa-let-7c, hsa-miR-23a, hsa-miR-23b, hsa-miR-223, hsa-miR-342-3p, hsa-miR-423-5p, hsa-miR-375, hsa-miR-99a, hsa-miR-150, hsa-miR-125b and hsa-miR-10a. The miRNA composition screened out by the invention and the primers of the miRNA composition have much higher specificity and flexibility for detecting HBV-positive people and HBV-positive patients with hepatocellular carcinoma than protein markers currently used in clinic, and therefore can greatly improve the accuracy of diagnosis. The miRNA composition and the primer composition thereof both can be used in the preparation of reagents and tools for detecting HBV infection and/or HBV-positive hepatocellular carcinoma.

The invention relates to a pulmonary tuberculosis variation activity marker, a kit, a method and a model construction method, and the pulmonary tuberculosis variation activity marker is characterized in that the pulmonary tuberculosis variation activity marker is a plasma protein biomarker in a blood sample, and the plasma protein biomarker is a combined marker comprising one or more of C1QB protein and CCL19 (MIP3B) protein; a combined marker of C1QB and CCL19 (MIP3B) is used as a biomarker for detecting the activity of pulmonary tuberculosis for the first time, a rapid diagnosis model for detecting the activity of pulmonary tuberculosis is constructed, a new direction is provided for clinical diagnosis of tuberculosis, and as a technical conception for diagnosing the activity of pulmonary tuberculosis, the biomarker provides a new target spot for the diagnosis of the active tuberculosis; therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for auxiliary diagnosis of tuberculosis activity.

The invention discloses a non-resistant low-zinc low-copper non-plasma high-grade piglet creep feed and a preparation method thereof. The creep feed comprises the following raw materials: corn, flour,broken rice, puffed soybean powder, milk powder, imported fish meal or fish peptide protein, fermented soybean meal, yeast hydrolysate, soybean protein concentrate, fat powder, acidifying agent, fishsolubles, egg powder, calcium lactate, calcium dihydrogen phosphate, lysine, methionine, threonine, tryptophan, trace element composite package, coated zinc oxide, vitamin composite package, plant extract composite package, plant essential oil, antibacterial peptide and microecological preparation. The product does not use homologous proteins such as plasma protein powder so as to effectively block the occurrence of homologous diseases. The product uses low zinc and low copper so as to reduce environmental pollution and improve the utilization rate of land. The product is free from antibioticso as to reduce drug residue and to ensure human food health. The preparation method provided by the invention is simple, the raw material sources are wide, and the use effect is good.

A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer.

The invention belongs to the technical field of immune assay medical detection and particularly provides a PIVKA-II (protein induced by vitamin K absence-II) magnetic particle chemiluminescence immuneassay determination kit and a preparation method thereof. The kit mainly comprises (1) a PIVKA-II standard product; (2) anti-FITC (fluorescein isothiocyanate) monoclonal antibody coated magnetic particles; (3) an alkaline phosphatase marked PIVKA-II sample and fluorescein isothiocyanate marked PIVKA-II; (4) an alkaline phosphatase marked chemiluminescent substrate; (5) subpackage of the standardproduct, magnetic particle solution, mixed solution, sample dilution liquid, washing liquid, the chemiluminescent substrate and reaction tubes. By combination of the enzyme marking technique, the magnetic particle separation technique and the chemiluminescence detection technique, an approximately homogenous reaction system is provided, and simplicity, sensitivity, high specificity, wide linear range, high repeatability and the like are realized.

The invention discloses a resurrection factor purification and extraction process for improving injection-type autologous fat survival rate. The process includes the steps: (a) collecting whole blood samples; (b) separating the whole blood samples; (c) fermenting the whole blood samples; (d) freezing fermentative supernatant liquid; (e) enabling whole blood sample cells to resuscitate; (f) performing purification and extraction for resurrection factors: adding liquid after standing into a centrifuging tube, performing secondary centrifugation for the liquid in a centrifugal machine, standing in the constant temperature environments after centrifugation, removing blood plasma on the upper layer of the centrifuging tube, adding new blood samples, and enabling sediment blood platelets to re-suspend to obtain the resurrection factors. According to the process, PRP (platelet-rich plasma) of autologous fat injection can be effectively extracted, extracting efficiency of the PRP from the cells is greatly improved, activities after autologous fat injection can be ensured, autologous fat injection operations are safer and more reliable, and the process is worthy of popularization.

The invention belongs to the technical field of membrane separation, and relates to a refining and extracting filtering preparation process of dextran. The method comprises the steps of: first, filtering a crude product liquor of dextran by a micro-filtration membrane; second, filtering the filtrate in the first step by a first ultrafiltration membrane; and third, filtering the filtrate in the second step by a second ultrafiltration membrane, wherein trapped fluid is the refined dextran, the mean pore size of the first ultrafiltration membrane is 20-100nm, and the mean pore size of the second ultrafiltration membrane is 2-20mn or the molecular weight cut-off is 3-100kDa. According to the invention, the membrane separation technology and the pharmaceutical process are combined to filter and refine a dextran raw material, so that a dextran product with narrower distribution of molecular weight is high in purity, is safe and reliable in curative effect and has high economic and beneficial benefits, and the product quality is improved.

Devices and methods are presented in which a plasma separation device with a first and second portion separates a blood containing fluid. Most preferably, the first portion produces a cell fraction and a plasma fraction, and the second portion captures the plasma fraction. A first actuator then fluidly isolates a portion of the plasma fraction within the second portion, and a second actuator moves the isolated portion of the plasma fraction from the second portion.

The invention belongs to the field of medical examination, and relates to an in vivo antibacterial drug content determination method, in particular to an online solid phase extraction liquid chromatography for detecting content of linezolid in blood. The online solid phase extraction liquid chromatography for detecting the content of linezolid in the blood performs pretreatment on a to-be-detectedblood sample and then determines the content of linezolid by virtue of a high performance liquid chromatograph and by adopting a standard curve method. The online solid phase extraction liquid chromatography for detecting linezolid drug concentration in the blood has the advantages that blood plasma is subjected to protein precipitation and then is directly injected, operation of personnel is reduced and accuracy of a quantitative result is improved.

The present invention relates to an improved method of purifying an immunoglobulin, and more particularly to a method of purifying an immunoglobulin which is capable of sufficiently removing impurities from an immunoglobulin-containing plasma protein sample through a simple process, comprising a single anion-exchange chromatography and a single cation-exchange chromatography.

The invention discloses medical equipment for platelet-rich plasma gel (PRG) in-vitro negative pressure cutting treatment, which comprises a box body, the box body is connected with a box cover through screws, the box body is provided with a sealing groove, the box cover is adhered with a silica gel ring, the sealing groove is internally and slidably connected with the silica gel ring, the box cover is provided with a lifting stirring mechanism, and the lifting stirring mechanism is connected with the box cover through screws. A high-speed cutting mechanism is arranged on the box body, an ultraviolet lamp is fixedly installed on the box cover, the side wall of the box body is fixedly sleeved with a PRP guide port, the side wall of the box body is fixedly sleeved with an activator guide port, a suction pump is fixedly installed on the side wall of the box body, and four supporting feet are welded to the box body and evenly distributed on the box body. The invention relates to medical equipment for PRP (Platelet Rich Plasma Gel) in-vitro negative pressure cutting treatment. The medical equipment has the characteristics that a relatively high sterile level can be kept when PRP is cut in vitro, and the cut PRP can be subjected to proper form cutting treatment aiming at tissues of different injured parts.

The invention discloses an immunoadsorption blood purification material and a preparation method thereof. The preparation method comprises the following steps: activating a solid-phase carrier by using CDI, and further covalently coupling ligand molecules with amino groups to obtain the immunoadsorption material. The method is simple in process, compared with an immunoadsorption carrier prepared from the same raw materials in the prior art, the immunoadsorption carrier is higher in pathogenic substance clearance rate, ligand molecules are not prone to falling off, and the immunoadsorption carrier can be used for plasma adsorption and can also be directly used for whole blood adsorption; meanwhile, small and medium molecular pathogenic substances such as urea and creatinine can be removed through hemodialysis or hemodialysis filtration. The amino-containing anticoagulant is introduced into the solid-phase carrier, so that the prepared immunoadsorption material has self-anticoagulant property, in the blood purification process, the additional anticoagulant can be reduced or even completely not used, and the risk of bleeding of a patient is greatly reduced.

The invention relates to a preparation method of thrombin, which comprises the following steps: filtering to remove impurities in porcine plasma; adding a virus inactivation reagent to perform virus inactivation treatment; adding an adsorbent to adsorb prothrombin; washing and immersing the prothrombin-adsorbed adsorbent, and dialyzing; activating the prothrombin in the dialyzed solution; regulating the pH value of the solution to 5.2-5.6, standing, centrifugating, regulating the pH value of the supernatant to 6.0-6.5, and standing; passing through a membrane adsorber, and eluting to obtain an eluate; filtering through an ultrafiltration membrane; filtering through a filter membrane for sterilization, and filtering through a filter with the pore size of 20nm to remove viruses; and preparing the preparation. On the basis of further stabilizing the titer of the thrombin product, the method effectively reduces the impurities in the thrombin product and the concentration of the impurity proteins, and implements virus removal after sufficient inactivation.

A dietary supplement comprising Coenzyme Q10 (i.e. ubiquinone) and a bioadhesive substance is described. Derivatives of Coenzyme Q10 may also be used in the dietary supplement. The dietary supplement may be provided to an individual to increase blood plasma levels of Coenzyme Q10.